ReviewSeminars in immunopathology2016
Adverse cutaneous drug eruptions: current understanding.
Review in Seminars in immunopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 171 citations in OpenAlex.
- Web application for assisting non-dermatology physicians in learning and managing patients with common cutaneous adverse drug reactions: a multicenter randomized controlled trial.Annals of medicine · 2024Trial
- Toxic Epidermal Necrolysis Mimicking Severe Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Diagnostic Challenge.Journal of clinical medicine · 2026Article
- A Rare Case of Stevens-Johnson Syndrome in a Young Patient Presenting With Odynophagia Following Antibiotic Use.The American journal of case reports · 2026Article
- Article
- Lamotrigine Therapy: Relation Between Treatment of Bipolar Affective Disorder and Incidence of Stevens-Johnson Syndrome-A Narrative Review of the Existing Literature.Journal of clinical medicine · 2025Review
- Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.PloS one · 2025Article
- Cross-Reactivity: a Case of Paracetamol-Induced Generalized Bullous Fixed Drug Eruption Followed by Dipyrone-Induced Fixed Drug Eruption.Clinical, cosmetic and investigational dermatology · 2025Article
- Severe Cutaneous Adverse Reactions in Hospitalized Children: A Pilot Validation Study.Pharmacoepidemiology and drug safety · 2024Article
- Dapagliflozin-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Followed by Acute Interstitial Nephritis (AIN).Internal medicine (Tokyo, Japan) · 2024Article
- Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs.International journal of molecular sciences · 2024Review
- How to Define and Manage Low-Risk Drug Allergy Labels.The journal of allergy and clinical immunology. In practice · 2024Review
- Review
- Evaluation of severe adverse cutaneous drug reactions in patients admitted to tertiary care center: A cross-sectional study.Health science reports · 2024Article
- Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years.Frontiers in immunology · 2024Article
- Article
- An association study ofiScience · 2023Article
- A Study of Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Andhra Pradesh, India.Cureus · 2023Article
- An Overview of Clinical Manifestations of Dermatological Disorders in Intensive Care Units: What Should Intensivists Be Aware of?Diagnostics (Basel, Switzerland) · 2023Review
- Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions.Dermatology (Basel, Switzerland) · 2023Article
- Maculopapular Drug Eruption Caused by Finasteride: A Case Report.Clinical, cosmetic and investigational dermatology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse cutaneous drug reactions are recognized as being major health problems worldwide causing considerable costs for health care systems. Most adverse cutaneous drug reactions follow a benign course; however, up to 2% of all adverse cutaneous drug eruptions are severe and life-threatening. These include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Physicians should be aware of specific red flags to rapidly identify these severe cutaneous drug eruptions and initiate appropriate treatment. Besides significant progress in clinical classification and treatment, recent studies have greatly enhanced our understanding in the pathophysiology of adverse cutaneous drug reactions. Genetic susceptibilities to certain drugs have been identified in SJS/TEN patients, viral reactivation in DRESS has been elucidated, and the discovery of tissue resident memory T cells helps to better understand the recurrent site-specific inflammation in patients with fixed drug eruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.